These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 27400948)

  • 21. The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017/GCIG.
    Kondo E; Tabata T; Suzuki N; Aoki D; Yahata H; Kotera Y; Tokuyama O; Fujiwara K; Kimura E; Terauchi F; Sumi T; Okamoto A; Yaegashi N; Enomoto T; Sugiyama T
    J Gynecol Oncol; 2020 Nov; 31(6):e94. PubMed ID: 33078599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.
    Gonzalez-Martin A; Gladieff L; Tholander B; Stroyakovsky D; Gore M; Scambia G; Kovalenko N; Oaknin A; Ronco JP; Freudensprung U; Pignata S;
    Eur J Cancer; 2013 Dec; 49(18):3831-8. PubMed ID: 24007819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
    Walker JL; Brady MF; Wenzel L; Fleming GF; Huang HQ; DiSilvestro PA; Fujiwara K; Alberts DS; Zheng W; Tewari KS; Cohn DE; Powell MA; Van Le L; Davidson SA; Gray HJ; Rose PG; Aghajanian C; Myers T; Alvarez Secord A; Rubin SC; Mannel RS
    J Clin Oncol; 2019 Jun; 37(16):1380-1390. PubMed ID: 31002578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.
    Nomura H; Aoki D; Michimae H; Mizuno M; Nakai H; Arai M; Sasagawa M; Ushijima K; Sugiyama T; Saito M; Tokunaga H; Matoda M; Nakanishi T; Watanabe Y; Takahashi F; Saito T; Yaegashi N;
    JAMA Oncol; 2019 Jun; 5(6):833-840. PubMed ID: 30896757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
    du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
    Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).
    Miller DS; Filiaci VL; Mannel RS; Cohn DE; Matsumoto T; Tewari KS; DiSilvestro P; Pearl ML; Argenta PA; Powell MA; Zweizig SL; Warshal DP; Hanjani P; Carney ME; Huang H; Cella D; Zaino R; Fleming GF
    J Clin Oncol; 2020 Nov; 38(33):3841-3850. PubMed ID: 33078978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.
    du Bois A; Lück HJ; Meier W; Adams HP; Möbus V; Costa S; Bauknecht T; Richter B; Warm M; Schröder W; Olbricht S; Nitz U; Jackisch C; Emons G; Wagner U; Kuhn W; Pfisterer J;
    J Natl Cancer Inst; 2003 Sep; 95(17):1320-9. PubMed ID: 12953086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of carboplatin and weekly irinotecan combination chemotherapy in recurrent ovarian cancer: a Kansai clinical oncology group study (KCOG0330).
    Tsubamoto H; Kawaguchi R; Ito K; Shiozaki T; Takeuchi S; Itani Y; Arakawa A; Tabata T; Toyoda S
    Anticancer Res; 2013 Mar; 33(3):1073-9. PubMed ID: 23482784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
    Ozols RF; Bundy BN; Greer BE; Fowler JM; Clarke-Pearson D; Burger RA; Mannel RS; DeGeest K; Hartenbach EM; Baergen R;
    J Clin Oncol; 2003 Sep; 21(17):3194-200. PubMed ID: 12860964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer.
    van der Burg ME; Vergote I; Onstenk W; Boere IA; Leunen K; van Montfort CA; van Doorn HC
    Eur J Cancer; 2013 Apr; 49(6):1254-63. PubMed ID: 23276720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.
    Pignata S; Scambia G; Ferrandina G; Savarese A; Sorio R; Breda E; Gebbia V; Musso P; Frigerio L; Del Medico P; Lombardi AV; Febbraro A; Scollo P; Ferro A; Tamberi S; Brandes A; Ravaioli A; Valerio MR; Aitini E; Natale D; Scaltriti L; Greggi S; Pisano C; Lorusso D; Salutari V; Legge F; Di Maio M; Morabito A; Gallo C; Perrone F
    J Clin Oncol; 2011 Sep; 29(27):3628-35. PubMed ID: 21844495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041).
    Nomura H; Aoki D; Takahashi F; Katsumata N; Watanabe Y; Konishi I; Jobo T; Hatae M; Hiura M; Yaegashi N
    Ann Oncol; 2011 Mar; 22(3):636-642. PubMed ID: 20696677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
    Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
    Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma.
    Socinski MA; Sandler AB; Israel VK; Gillenwater HH; Miller LL; Locker PK; Antonellini A; Elfring GL; Natale RB
    Cancer; 2002 Oct; 95(7):1520-7. PubMed ID: 12237921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer.
    Lhommé C; Joly F; Walker JL; Lissoni AA; Nicoletto MO; Manikhas GM; Baekelandt MM; Gordon AN; Fracasso PM; Mietlowski WL; Jones GJ; Dugan MH
    J Clin Oncol; 2008 Jun; 26(16):2674-82. PubMed ID: 18509179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
    Spigel DR; Luft A; Depenbrock H; Ramlau R; Khalil M; Kim JH; Mayo C; Chao GY; Obasaju C; Natale R
    Clin Lung Cancer; 2017 Sep; 18(5):480-488. PubMed ID: 28365238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.
    International Collaborative Ovarian Neoplasm Group
    Lancet; 2002 Aug; 360(9332):505-15. PubMed ID: 12241653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.